DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis

Information source: North Shore Long Island Jewish Health System
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Recurrent Respiratory Papillomatosis

Intervention: celebrex (celecoxib) (Drug); placebo capsules (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: North Shore Long Island Jewish Health System

Official(s) and/or principal investigator(s):
Bettie M Steinberg, PhD, Principal Investigator, Affiliation: Long Island Jewish Medical Center

Summary

This is a randomized double blind controlled study to determine if celebrex (celecoxib), a selective COX-2 inhibitor, can decrease the rate of recurrence in adult and pediatric patients with recurrent respiratory papillomatosis. All patients will be evaluated for disease severity at enrollment and at 3 month intervals for 30 months. After randomization, patients in the early treatment arm will begin celecoxib 6 months after enrollment. The delayed treatment arm will begin celecoxib 18 months after enrollment. All patients will receive celecoxib for 1 year. During the time that patients do no receive celecoxib, they will receive a placebo capsule with the same appearance. Follow-up visits will occur at three month intervals for the duration of the study.

Clinical Details

Official title: A Multicentered Randomized Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: What is the efficacy of celebrex response relative to conventional endoscopy and surgical removal in reducing recurrence,and is improvement maintained when celecoxib therapy stops?

Secondary outcome:

Do any clinical characteristics (age of onset, gender, HPV type) predict response?

Do molecular markers suggest inhibitions of COX-2 as mechanism of response?

Does celebrex reduce persistence of HPV DNA or alter HPV expression.

Detailed description: This is a randomized double blind placebo-controlled study,with plans to include 5 additional U. S. centers in the near future. The primary goal of this study is to determine whether celecoxib has efficacy in elimination or reduction of recurrent disease in patients with RRP. Our secondary goals are to determine whether continued celecoxib is required to maintain response, to correlate response with select patient demographics and persistence of latent HPV DNA, and to determine whether celecoxib is acting through inhibition of COX-2, in order to begin to determine mechanism of effects in vivo on RRP. The study design encompasses a 30-month period, which can be divided into three segments: Segment A: This is a 6 month run-in period in which all patients are assessed by direct laryngoscopy/bronchoscopy for disease severity, to permit growth rate stabilization and confirm accuracy of training of participating physicians. Patients will be treated by conventional surgery at three months and six months after enrollment. Segment B: Patients begin 12 months of 400mg(adults), 100 mg (pediatric weight between 12 and 25 kg)or 200 mg (pediatric weight > 25kg) celecoxib daily or placebo treatment in addition to surgical removal of all papillomas at each 3 month interval. This segment directly tests the hypothesis that celecoxib is an efficacious treatment for moderate to severe RRP and forms the basis for the primary statistical analyses. Segment C: The primary purpose of this segment is to determine whether gains made during celecoxib therapy are maintained after it is discontinued, or whether celecoxib will need to be taken indefinitely. This will be determined by a 12 month period on placebo after cessation of celecoxib for the early treatment group.

Eligibility

Minimum age: 2 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Moderate to severe disease, defined as:

Patients who have rapid regrowth of papillomas, requiring endoscopic removal at least 3 times within the past 12 months AND A papilloma growth rate from 0. 03 to 0. 06 (moderate) or >0. 06 (severe) at time of initial direct endoscopy OR Having tracheal and/or bronchial or pulmonary papillomatosis (severe)

- Age > 2 years

- Gender- no restriction

- Race- no restriction

Exclusion Criteria:

- Fewer than 3 surgical procedures in previous year, without tracheal disease

- Age < 2 years

- Pregnancy, trying to become pregnant, breastfeeding or not willing to comply with

birth control methods if sexually active female

- Serum creatinine > 1. 5 X normal

- History of documented peptic ulcer disease or gastritis persisting despite treatment

- Abnormal liver function tests, as total bilirubin >1. 5 X normal and SGOT > 3 X normal

- Allergy to NSAIDs, sulfa containing drugs or symptoms of Stevens-Johnson Syndrome

- Patients with connective tissue diseases such as SLE, Raynaud's or Systemic Sclerosis

- Patients with known diabetes

- Patients on warfarin, or on loop or thiazide diuretics

- Patients with a history of cardiovascular disease, myocardial infarct or stroke

- Patients with congestive heart failure

- Patients regularly taking > 81 mg of aspirin/day

- Patients with uncontrolled hypertension

- Patients with RRP associated malignancy currently receiving chemotherapy and/or

radiation

Locations and Contacts

University of Alabama Birmingham, Birmingham, Alabama 35294, United States

UCSF Medical Center, San Francisco, California 94115, United States

University of Iowa, Iowa City, Iowa 52242, United States

Long Island Jewish Medical Center, New Hyde Park, New York 11040, United States

Sanford Health /USD, Sioux Falls, South Dakota 57104, United States

Vanderbilt University, Nashville, Tennessee 37232, United States

Eastern Virginia Medical School, Norfolk, Virginia 23507, United States

Additional Information

Related publications:

Wu R, Abramson AL, Shikowitz MJ, Dannenberg AJ, Steinberg BM. Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas. Clin Cancer Res. 2005 Sep 1;11(17):6155-61.

Starting date: February 2008
Last updated: May 13, 2015

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017